Nearly three-fourths of patients with previously untreated advanced NSCLC with specific mutations of EGFR experienced one full year of PFS when given the investigational therapeutic agent dacomitinib.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Fast Track Designation to FRα-Targeting ADC for Ovarian Cancer
2
FDA Regulatory Highlights in Oncology: March 2026
3
FDA Grants Lirafugratinib Priority Review in FGFR2-Altered Cholangiocarcinoma
4
Therapeutic Resistance and High-Risk Subsets in Advanced Melanoma
5